Compare Boston Scientific Corporation (BSX) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Expedia Group Inc — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Expedia Group Inc trades at $266.28 (market cap $31.96B). The key difference: Boston Scientific Corporation is far larger — about 2.1× Expedia Group Inc's market cap, and Expedia Group Inc pays a 0.66% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | EXPE | |
|---|---|---|
Market Cap | $66.37B | $31.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $301.31 |
52-Week Low | $42.63 | $178.06 |
Enterprise Value | $75.94B | $30.87B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Expedia Group (EXPE) trades at $265.63, down 1.92% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $287.90 implying 8.4% upside. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.96 surpassing expectations of $1.41. Revenue grew to $14.73B in 2025, and net income reached $1.29B, supported by a high gross profit margin of 90.27%. Recent developments include a strategic partnership with Allegiant Travel and upcoming Q2 2026 earnings on August 5, 2026.
The outlook for EXPE is positive, driven by earnings momentum, strategic partnerships, and analyst optimism, but risks include travel sector volatility and high debt levels. The stock presents a growth opportunity with reasonable valuation multiples (P/E 23.47, EV/EBITDA 9.99), though investors should monitor competitive pressures and macroeconomic impacts on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
